**Evidence Table E-20. Contrast induced nephropathy outcomes in studies comparing statin plus IV saline versus IV saline with or without placebo that are not included in the meta-analysis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Measure** | **SG** | **Intervention** | **Arm** | **Time Point 1**  |  **Time point 1 N analyzed** | **n (%) with outcome at time point 1** | **Comparison\* statistics at time point 1** | **Time Point 2**  | **Time point 2 N anlyzed**  | **n (%) with outcome at timepoint 2** | **Comparison statistics at time point 2** |
| Abaci, 2015[1](#_ENREF_1) | Incidence of CIN |  | IV normal saline | 1 | 48-72 hours | 105 | 9 (8.5) | P=0.44 |  |  |  |  |
| Abaci, 2015[1](#_ENREF_1) | Incidence of CIN |  | Risovustain + IV normal saline | 2 | 48-72 hours | 103 | 6 (5.8) |  |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | SCr ≥0.5 mg/dl or ≥25% from baseline |  | Oral Atorvastatin + IV Normal Saline | 2 | 48 hours | 98 | 9 (9.2) | p=0.50 |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | SCr ≥0.5 mg/dl or ≥25% from baseline |  | Oral Rosuvastatin + IV Normal Saline | 3 |  | 94 | 5 (5.3) |  |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | SCr ≥0.5 mg/dl from baseline |  | Oral Atorvastatin + IV Normal Saline | 2 | 48 hours | 98 | 1 (1) | p=NR |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | SCr ≥0.5 mg/dl from baseline |  | Oral Rosuvastatin + IV Normal Saline | 3 |  | 94 | 2 (2.1) |  |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | Predictors of CIN, SCr ≥0.5 mg/dl or ≥25% from baseline | LVEF % | Oral Atorvastatin + IV Normal Saline | 2 | 48 hours | 98 |  | Multivariate OR: 0.88 (95% CI: 0.77-1.01)p=0.07 |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | Predictors of CIN, SCr ≥0.5 mg/dl or ≥25% from baseline | LVEF % | Oral Rosuvastatin + IV Normal Saline | 3 |  | 94 |  |  |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | Predictors of CIN, SCr ≥0.5 mg/dl or ≥25% from baseline | Contrast media (ml) | Oral Atorvastatin + IV Normal Saline | 2 | 48 hours | 98 |  | Multivariate OR: 0.1.08 (95% CI: 1.03-1.13)P<0.001 |  |  |  |  |
| Kaya, 2013[56](#_ENREF_56) | Predictors of CIN, SCr ≥0.5 mg/dl or ≥25% from baseline | Contrast media (ml) | Oral Rosuvastatin + IV Normal Saline | 3 |  | 94 |  |  |  |  |  |  |

**Evidence Table E-20. Contrast induced nephropathy outcomes in studies comparing statin plus IV saline versus IV saline with or without placebo that are not included in the meta-analysis (continued)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Measure** | **SG** | **Intervention** | **Arm** | **Time Point 1**  |  **Time point 1 N analyzed** | **n (%) with outcome at time point 1** | **Comparison\* statistics at time point 1** | **Time Point 2**  | **Time point 2 N anlyzed**  | **n (%) with outcome at timepoint 2** | **Comparison statistics at time point 2** |
| Li, 2014[73](#_ENREF_73) | increase in serum creatinine (SCr) of > 0.5 mg/dl or >25% from baseline |  | Standard atorvastatin + probucol dose | 1 | 24 hours | 55 | 1 (1.8) | p=NR |  |  |  |  |
| Li, 2014[73](#_ENREF_73) | increase in serum creatinine (SCr) of > 0.5 mg/dl or >25% from baseline |  | Large atorvastatin + probucol dose | 2 |  | 79 | 1 (1.3) |  |  |  |  |  |
| Li, 2014[73](#_ENREF_73) | increase in serum creatinine (SCr) of > 0.5 mg/dl or >25% from baseline |  | Large atorvastatin dose | 3 |  | 74 | 0 |  |  |  |  |  |
| Liu, 2014[74](#_ENREF_74) | Incidence of CIN |  | Risovustatin | 2 | 72 hours |  | (5.9) | P=0.68 |  |  |  |  |
| Liu, 2014[74](#_ENREF_74) | Incidence of CIN |  | Atorvastatin | 3 | 72 hours |  | (5.2) |  |  |  |  |  |
| Ozhan, 2010[88](#_ENREF_88) | Incidence of CIN |  | NAC + IV normal saline  | 2 | 48 hours | 70 | 7 (10) | p=0.135 |  |  |  |  |
| Ozhan, 2010[88](#_ENREF_88) | Incidence of CIN |  | NAC + Atorvastatin +IV normal saline | 3 |  | 60 | 2 (3.3) |  |  |  |  |  |
| Quintavalle, 2012[92](#_ENREF_92) | Increase in serum creatinine >0.5mg.dl |  | NAC + IV NaHCO3 | 2 | 48 hours | 208 | 16 (7.7) | p=0.085 |  |   |  |  |
| Quintavalle, 2012[92](#_ENREF_92) | Increase in serum creatinine >0.5mg.dl |  | Atorvastatin + NAC + IV NaCO3 | 3 |   | 202 | 7 (3.5) |  |  |   |  |  |

**Evidence Table E-20. Contrast induced nephropathy outcomes in studies comparing statin plus IV saline versus IV saline with or without placebo that are not included in the meta-analysis (continued)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Measure** | **SG** | **Intervention** | **Arm** | **Time Point 1**  |  **Time point 1 N analyzed** | **n (%) with outcome at time point 1** | **Comparison\* statistics at time point 1** | **Time Point 2**  | **Time point 2 N anlyzed**  | **n (%) with outcome at timepoint 2** | **Comparison statistics at time point 2** |
| Quintavalle, 2012[92](#_ENREF_92) | Increase in serum creatinine >25% from baseline |  | NAC + IV NaHCO3 | 2 | 48 hours | 208 | 14 (7) | p=0.10 |  |   |  |  |
| Quintavalle, 2012[92](#_ENREF_92) | Increase in serum creatinine >25% from baseline |  | Atorvastatin + NAC + IV NaCO3 | 3 |   | 202 | 6 (3) |  |  |   |  |  |
| Qiao, 2015[91](#_ENREF_91) | Incidence of CIN |  | IV saline | 1 | 72 hours | 60 | 2 (0.03) | P=NR |  |  |  |  |
| Qiao, 2015[91](#_ENREF_91) | Incidence of CIN |  | Rosuvastatin + IV Saline | 2 |  | 60 | 2 (0.03) |  |  |  |  |  |
| Sanei, 2014[98](#_ENREF_98) | Incidence of CIN |  | Placebo | 1 | 72 hours | NR |  | P=0.535 |  |  |  |  |
| Sanei, 2014[98](#_ENREF_98) | Incidence of CIN |  | Atorvatatin | 2 |  | NR |  |  |  |  |  |  |
| Shehata, 2015[102](#_ENREF_102) | Incidence of CIN |  | IV saline + oral NAC | 1 | 72 hours | 65 | 13 (20) | P<0.05 |  |  |  |  |
| Shehata, 2015[102](#_ENREF_102) | Incidence of CIN  |  | Atorvastatin + IV saline + oral NAC | 2 |  | 65 | 5 (7.7) |  |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN, primary definition |   | Placebo + IV normal saline + NAC | 1 | 5 days |  | 16 (11) | p=0.86 |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN, primary definition |   | atorvastatin + IV normal saline + NAC | 2 |  |  | 15 (10) |  |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN, secondary definition |   | Placebo + IV normal saline + NAC | 1 | 5 days | 152 |  (15) | p=0.67 |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN, secondary definition |   | atorvastatin + IV normal saline + NAC | 2 |  | 152 |  (17) |  |  |  |  |  |

**Evidence Table E-20. Contrast induced nephropathy outcomes in studies comparing statin plus IV saline versus IV saline with or without placebo that are not included in the meta-analysis (continued)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Measure** | **SG** | **Intervention** | **Arm** | **Time Point 1**  |  **Time point 1 N analyzed** | **n (%) with outcome at time point 1** | **Comparison\* statistics at time point 1** | **Time Point 2**  | **Time point 2 N anlyzed**  | **n (%) with outcome at timepoint 2** | **Comparison statistics at time point 2** |
| Toso, 2010[109](#_ENREF_109) | incidence of CIN | Age >=75 years | Placebo + IV normal saline + NAC | 1 | 5 days | 97 | 12 (12) | p=0.98 |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | incidence of CIN | Age >=75 years | atorvastatin + IV normal saline + NAC | 2 |  | 80 | 10(13) |  |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN | High-very High CIN risk score (>=11) | Placebo + IV normal saline + NAC | 1 | 5 days | 65 | 4 (6) | p=0.63 |  |  |  |  |
| Toso, 2010[109](#_ENREF_109)  | Incidence of CIN | High-very High CIN risk score (>=11) | atorvastatin + IV normal saline + NAC | 2 |  | 57 | 6 (11) |  |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN | LVEF <40% | Placebo + IV normal saline + NAC | 1 | 5 days | 49 | 10 (20) | p=0.37 |  |  |  |  |
| Toso, 2010[109](#_ENREF_109) | Incidence of CIN | LVEF <40% | atorvastatin + IV normal saline + NAC | 2 |  | 41 | 4 (10) |  |  |  |  |  |
| Xinwei, 2009[116](#_ENREF_116) | postprocedure increase in serum creatinine of >/= 44.2 umol/L (0.5 mg/dl) or >25% from baseline |  | Simvastatin 20mg + IV NS | 2 | 24 hours | 115 | 16 (13.9) | p<0.5 | 48 hours | 115 | 18 (15.7) | p<0.5 |
| Xinwei, 2009[116](#_ENREF_116) | postprocedure increase in serum creatinine of >/= 44.2 umol/L (0.5 mg/dl) or >25% from baseline |  | Simvastatin 80mg + IV NS | 3 |  24 hours | 113 | 6 (5.3) |  |   | 113 | 6 (5.3) |  |

**Evidence Table E-20. Contrast induced nephropathy outcomes in studies comparing statin plus IV saline versus IV saline with or without placebo that are not included in the meta-analysis (continued)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Measure** | **SG** | **Intervention** | **Arm** | **Time Point 1**  |  **Time point 1 N analyzed** | **n (%) with outcome at time point 1** | **Comparison\* statistics at time point 1** | **Time Point 2**  | **Time point 2 N anlyzed**  | **n (%) with outcome at timepoint 2** | **Comparison statistics at time point 2** |
| Yun, 2014[118](#_ENREF_118) | Incidence of CIN |  | IV normal saline | 1 | 72 hours | 416 | (18.8) | P=0.040 |  |  |  |  |
| Yun, 2014[118](#_ENREF_118) | Incidence of CIN |  | Risovustatin + IV normal saline | 2 |  | 408 | (13.5) |  |  |  |  |  |
| Zhang, 2015[119](#_ENREF_119) | Incidence of CIN (moderate dose) |  | Placebo | 1 | 72 hours | 355 | 16 (4.5) | P=0.029 |  |  |  |  |
| Zhang, 2015[119](#_ENREF_119) | Incidence of CIN (moderate dose) |  | Rosuvastatin | 2 |  | 357 | 6 (1.7) |  |  |  |  |  |
| Zhang, 2015[119](#_ENREF_119) | Incidence of CIN (high dose) |  | Placebo | 1 | 72 hours | 102 | 4 (3.9) | P=0.834 |  |  |  |  |
| Zhang, 2015[119](#_ENREF_119) | Incidence of CIN (high dose) |  | Rosuvastatin | 2 |  | 118 | 4 (3.4) |  |  |  |  |  |

%=percent; CI=confidence interval; CIN=contrast induced nephropathy; CRF=chronic renal failure; GFR=glomerular filtration rate; Hrs=hours; LVEF=left ventricular ejection fraction; Mg/dl=milligram per deciliter; Mg=milligram; N=sample size; OR=odds ratio; P=p-value; SCr=serum creatinine; SG=subgroups; Umol/l=micromole per liter